FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 326:156-160 January 16, 1992 Number 3 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Numerous reports suggest that allogeneic bone marrow transplantation prolongs the survival of adult patients with acute myelogenous leukemia (AML) in first remission. However, it is unclear how many such patients actually undergo this procedure. METHODS. We reviewed the case records of 350 consecutive adult patients with AML treated with chemotherapy at a single institution from 1979 (when the policy of offering allogeneic transplantation to all such patients in first remission was introduced) through 1990. The criteria for exclusion before transplantation included age greater than 40 and, beginning in 1984, a diagnosis of acute promyelocytic leukemia. RESULTS. One hundred forty-two patients (41 percent of the study population) were 40 years of age or under. HLA testing was performed for 120 of these patients (85 percent). Sixty-seven patients (47 percent) had an HLA-identical sibling as a potential donor. One hundred three patients (73 percent) entered remission during treatment according to one of five chemotherapy protocols. Of the 52 patients who both entered remission and had an HLA match, 30 underwent transplantation while they were in first remission. These 30 patients constituted 21 percent of all study patients 40 years old or under, 29 percent of all patients 40 or under who entered remission, 45 percent of all patients with an HLA match, 58 percent of all patients who had both a remission and a match, and 9 percent of all patients treated according to a protocol. Among patients with a match who did not undergo transplantation, those with primary refractory disease were the largest subgroup. CONCLUSIONS. These findings suggest that allogeneic bone marrow transplantation is performed in less than 60 percent of adult patients with AML who are potentially eligible for the procedure.

Source Information

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York 10021.

This article has been cited by other articles:

• Nathan, P. C., Sung, L., Crump, M., Beyene, J. (2004). Consolidation Therapy With Autologous Bone Marrow Transplantation in Adults With Acute Myeloid Leukemia: A Meta-analysis. JNCI J Natl Cancer Inst 96: 38-45 [Abstract] [Full Text]  
• Stull, D. M. (2002). Current Trends in the Treatment of Acute and Chronic Myelogenous Leukemia. Journal of Pharmacy Practice 15: 62-74 [Abstract]  
• Tallman, M. S., Rowlings, P. A., Milone, G., Zhang, M.-J., Perez, W. S., Weisdorf, D., Keating, A., Gale, R. P., Geller, R. B., Laughlin, M. J., Lazarus, H. M., Luger, S. M., McCarthy, P. L., Rowe, J. M., Saez, R. A., Vowels, M. R., Horowitz, M. M. (2000). Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 96: 1254-1258 [Abstract] [Full Text]  
• Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., Frei, E., The Cancer and Leukemia Group B, (1994). Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia. NEJM 331: 896-903 [Abstract] [Full Text]